{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T18:33:21Z","timestamp":1794940401122,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]},{"name":"Medical Research Council","award":["MR\/W029162\/1"],"award-info":[{"award-number":["MR\/W029162\/1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Drug-related deaths have substantially increased over the past decade in the UK, particularly in Scotland. Co-use of opioids and benzodiazepines (prescribed and\/or illicit) is contributing to rising mortality. This study identified motivations in people\u2019s co-use with the aim of informing prescribing and harm reduction interventions to address drug-related deaths.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We interviewed 48 people who co-use opioids and benzodiazepines and\/or z-drugs (zopiclone and zolpidem) in Glasgow (<jats:italic>n<\/jats:italic>\u2009=\u200928), Teesside (<jats:italic>n<\/jats:italic>\u2009=\u200910) and Bristol (<jats:italic>n<\/jats:italic>\u2009=\u200910). Most participants self-identified as male (<jats:italic>n<\/jats:italic>\u2009=\u200937, 77%), white (<jats:italic>n<\/jats:italic>\u2009=\u200945, 94%) and had a mean age of 43 years (range: 25\u201361 years). The majority reported at least one overdose experience, and poor mental health including trauma. Interviews were semi-structured, conducted by an academic and\/or peer researcher, and analysed using reflexive thematic analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Participants\u2019 motivations for co-using mapped onto two interlinked meta-themes: (1) Functional motivations included co-using to augment drug effects, self-medicate or help to generate income. (2) Experiential motivations described participants\u2019 desires to achieve a \u2018buzz\u2019 (feeling energised), \u2018glow\u2019 (feeling comforted), \u2018oblivion\u2019 (escaping trauma and adversity), and \u2018gouching\u2019 (physical and mental sensations of ebbing in and out of glow and oblivion). Functional and experiential motivations were dynamic, interrelated and often co-occurred.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The importance of assessing motivations to co-use should be routinely recognised as part of harm reduction and medication assisted treatments to reduce mortality risk.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12954-025-01312-x","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:09:09Z","timestamp":1759165749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study"],"prefix":"10.1186","volume":"22","author":[{"given":"Gabriele","family":"Vojt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Family","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Cavallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula","family":"Abdala Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Kesten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"1312_CR1","unstructured":"World Health Organization. Opioid overdose. World Health Organization. 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"key":"1312_CR2","unstructured":"Scottish Government. National Drugs Mission Plan: 2022\u20132026. Scottish Government; 2022. https:\/\/www.gov.scot\/publications\/national-drugs-mission-plan-2022-2026\/pages\/3\/"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: A systematic review. Drug Alcohol Depend. 2019;200:95\u2013114.","journal-title":"Drug Alcohol Depend"},{"key":"1312_CR4","unstructured":"Dhaliwal A, Gupta M, Physiology. Opioid Receptor. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546642\/"},{"key":"1312_CR5","unstructured":"Joint Formulary Committee. British National Formulary: Hypnotics and anxiolytics London: BMJ and Pharmaceutical Press; 2025. https:\/\/bnf.nice.org.uk\/treatment-summaries\/hypnotics-and-anxiolytics\/"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"100489","DOI":"10.1016\/j.lanepe.2022.100489","volume":"22","author":"E Domzaridou","year":"2022","unstructured":"Domzaridou E, Carr MJ, Webb RT, Millar T, Ashcroft DM. Non-fatal overdose risk during and after opioid agonist treatment: A primary care cohort study with linked hospitalisation and mortality records. Lancet Reg Health\u2013Europe. 2022;22:100489.","journal-title":"Lancet Reg Health\u2013Europe"},{"key":"1312_CR7","unstructured":"Black C. Review of drugs part two: prevention, treatment, and recovery; 2021. https:\/\/www.gov.uk\/government\/publications\/review-of-drugs-phase-two-report\/review-of-drugs-part-two-prevention-treatment-and-recovery#foreword"},{"issue":"5","key":"1312_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3390\/pharmacy12050152","volume":"12","author":"C Matheson","year":"2024","unstructured":"Matheson C, Vucic C, Dumbrell J, Robertson R, Ritchie T, Duncan C, et al. Clinical outcomes of benzodiazepine prescribing for people receiving opioid agonist treatment: A systematic review of the evidence. Pharmacy. 2024;12(5):152.","journal-title":"Pharmacy"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"103512","DOI":"10.1016\/j.drugpo.2021.103512","volume":"100","author":"A McAuley","year":"2022","unstructured":"McAuley A, Matheson C, Robertson J. From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic. Int J Drug Policy. 2022;100:103512.","journal-title":"Int J Drug Policy"},{"key":"1312_CR10","unstructured":"Scottish Drugs Forum. Drug-related deaths in Scotland MSP Briefing; 2021. https:\/\/sdf.org.uk\/wp-content\/uploads\/2024\/05\/Drug-related-deaths-in-Scotland-MSP-Briefing.pdf"},{"issue":"2","key":"1312_CR11","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/S2468-2667(21)00254-1","volume":"7","author":"D Lewer","year":"2022","unstructured":"Lewer D, Brothers TD, Hest NV, Hickman M, Holland A, Padmanathan P, et al. Causes of death among people who used illicit opioids in england, 2001\u201318: a matched cohort study. Lancet Public Health. 2022;7(2):e126\u201335.","journal-title":"Lancet Public Health"},{"key":"1312_CR12","unstructured":"Mental Welfare Commission for Scotland. Ending the exclusion: Care, treatment and support for people with mental ill health and problem substance use in Scotland. 2022. https:\/\/www.mwcscot.org.uk\/sites\/default\/files\/2022-09\/EndingTheExclusion_September2022.pdf"},{"key":"1312_CR13","unstructured":"Scottish Government. Medication Assisted Treatment (MAT) standards: access, choice, support. 2021. https:\/\/www.gov.scot\/publications\/medication-assisted-treatment-mat-standards-scotland-access-choice-support"},{"key":"1312_CR14","unstructured":"Public Health Scotland. MAT standards informed response for benzodiazepine harm reduction Call to action; 2023. https:\/\/publichealthscotland.scot\/media\/24430\/mat-standards-informed-response-for-benzodiazepine-harm-reduction-guidance-december2023.pdf"},{"key":"1312_CR15","unstructured":"Division of Clinical Psychology. Good practice guidelines on the use of psychological formulation; 2011."},{"key":"1312_CR16","volume-title":"Drug misuse and dependence: UK guidelines on clinical management","author":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group","year":"2017","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health; 2017."},{"key":"1312_CR17","unstructured":"Association of Clinical Psychologists UK. Team Formulation: Key Considerations in Mental Health Services; 2022. https:\/\/acpuk.org.uk\/team-formulation-key-considerations-in-mental-health-services\/"},{"issue":"1","key":"1312_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10615-016-0584-3","volume":"45","author":"SP Vakharia","year":"2017","unstructured":"Vakharia SP, Little J. Starting where the client is: harm reduction guidelines for clinical social work practice. Clin Soc Work J. 2017;45(1):65\u201376.","journal-title":"Clin Soc Work J"},{"key":"1312_CR19","doi-asserted-by":"crossref","unstructured":"Cox WM, Klinger E. Handbook of motivational counseling. Wiley; 2011.","DOI":"10.1002\/9780470979952"},{"issue":"10","key":"1312_CR20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1016\/j.addbeh.2013.05.008","volume":"38","author":"M Vogel","year":"2013","unstructured":"Vogel M, Kn\u00f6pfli B, Schmid O, Prica M, Strasser J, Prieto L, et al. Treatment or high: benzodiazepine use in patients on injectable heroin or oral opioids. Addict Behav. 2013;38(10):2477\u201384.","journal-title":"Addict Behav"},{"issue":"4","key":"1312_CR21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jsat.2009.03.006","volume":"37","author":"M Fats\u00e9as","year":"2009","unstructured":"Fats\u00e9as M, Lavie E, Denis C, Auriacombe M. Self-perceived motivation for benzodiazepine use and behavior related to benzodiazepine use among opiate-dependent patients. J Subst Abuse Treat. 2009;37(4):407\u201311.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"1312_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.24095\/hpcdp.42.2.01","volume":"42","author":"M Boileau-Falardeau","year":"2022","unstructured":"Boileau-Falardeau M, Contreras G, Gari\u00e9py G, Laprise C. Patterns and motivations of polysubstance use: a rapid review of the qualitative evidence. Health Promot Chronic Dis Prev Can. 2022;42(2):47\u201359.","journal-title":"Health Promot Chronic Dis Prev Can"},{"issue":"1","key":"1312_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12954-025-01153-8","volume":"22","author":"HE Family","year":"2025","unstructured":"Family HE, Vojt G, Poulter H, Bailey CP, Abdala Sheikh AP, Cavallo D, Karimi S, Booth N, Da Silva P, Aitken L, Stewart S, Hickman M, Henderson G, Scott J, Kesten JM. A qualitative study of benzodiazepine\/z-drug and opioid co-use patterns and overdose risk. Harm Reduct J. 2025;22(1):24.","journal-title":"Harm Reduct J"},{"issue":"4","key":"1312_CR24","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/bcp.14397","volume":"87","author":"J Hockenhull","year":"2020","unstructured":"Hockenhull J, Black JC, Haynes CM, Rockhill K, Dargan PI, Dart RC, et al. Nonmedical use of benzodiazepines and Z-drugs in the UK. Br J Clin Pharmacol. 2020;87(4):1676\u201383.","journal-title":"Br J Clin Pharmacol"},{"key":"1312_CR25","volume-title":"Russian roulette\u2019: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?","author":"H Poulter","year":"2024","unstructured":"Poulter H, Vojt G, Family H, Bailey C, Abdalal Sheikh AP, Cavallo D, et al. Russian roulette\u2019: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction? Lisbon: Lisbon Addictions; 2024."},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"1129447","DOI":"10.3389\/fpsyt.2023.1129447","volume":"14","author":"RK McHugh","year":"2023","unstructured":"McHugh RK, Votaw VR, Trapani EW, McCarthy MD. Prevalence and correlates of the misuse of z-drugs and benzodiazepines in the National survey on drug use and health. Front Psychiatry. 2023;14:1129447.","journal-title":"Front Psychiatry"},{"issue":"13","key":"1312_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"issue":"4","key":"1312_CR28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/109019818801500401","volume":"15","author":"KR McLeroy","year":"1988","unstructured":"McLeroy KR, Bibeau D, Steckler A, Glanz K. An ecological perspective on health promotion programs. Health Educ Q. 1988;15(4):351\u201377.","journal-title":"Health Educ Q"},{"issue":"4","key":"1312_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health. 2019;11(4):589\u201397.","journal-title":"Qual Res Sport Exerc Health"},{"issue":"4","key":"1312_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/2167702620978614","volume":"9","author":"VR Votaw","year":"2021","unstructured":"Votaw VR, Witkiewitz K. Motives for substance use in daily life: a systematic review of studies using ecological momentary assessment. Clin Psychol Sci. 2021;9(4):535\u201362.","journal-title":"Clin Psychol Sci"},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"102823","DOI":"10.1016\/j.drugpo.2020.102823","volume":"82","author":"T May","year":"2020","unstructured":"May T, Holloway K, Buhociu M, Hills R. Not what the Doctor ordered: motivations for nonmedical prescription drug use among people who use illegal drugs. Int J Drug Policy. 2020;82:102823.","journal-title":"Int J Drug Policy"},{"key":"1312_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.drugpo.2017.07.005","volume":"49","author":"T Duncan","year":"2017","unstructured":"Duncan T, Duff C, Sebar B, Lee J. Enjoying the kick: locating pleasure within the drug consumption room. Int J Drug Policy. 2017;49:92\u2013101.","journal-title":"Int J Drug Policy"},{"key":"1312_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.addbeh.2016.08.020","volume":"65","author":"RK McHugh","year":"2017","unstructured":"McHugh RK, Votaw VR, Bogunovic O, Karakula SL, Griffin ML, Weiss RD. Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder. Addict Behav. 2017;65:283\u20138.","journal-title":"Addict Behav"},{"key":"1312_CR34","doi-asserted-by":"crossref","unstructured":"Department of Health and Social Care. 10 year health plan for England: fit for the future; 2025. https:\/\/www.gov.uk\/government\/publications\/10-year-health-plan-for-england-fit-for-the-future","DOI":"10.12968\/jokc.2025.10.5.212"},{"key":"1312_CR35","first-page":"CD010523","volume":"3","author":"A Coulter","year":"2015","unstructured":"Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev. 2015;3:CD010523.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"1312_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0005-7967(96)00119-2","volume":"35","author":"NE Turner","year":"1997","unstructured":"Turner NE, Annis HM, Sklar SM. Measurement of antecedents to drug and alcohol use: psychometric properties of the inventory of Drug-Taking situations (IDTS). Behav Res Ther. 1997;35(5):465\u201383.","journal-title":"Behav Res Ther"},{"issue":"8","key":"1312_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.euroneuro.2009.04.001","volume":"19","author":"E Peles","year":"2009","unstructured":"Peles E, Schreiber S, Adelson M. Documented poor sleep among methadone-maintained patients is associated with chronic pain and benzodiazepine abuse, but not with methadone dose. Eur Neuropsychopharmacol. 2009;19(8):581\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1312_CR38","doi-asserted-by":"crossref","unstructured":"Correa VC, Lugo-Agudelo LH, Aguirre-Acevedo DC, Contreras JAP, Borrero AMP, Pati\u00f1o-Lugo DF et al. Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: a systematic metareview. Health Res Policy Syst. 2020;18(1).","DOI":"10.1186\/s12961-020-00588-8"},{"key":"1312_CR39","unstructured":"Scottish Drugs Forum. Identifying & preventing burnout in frontline services for people who use drugs & alcohol; 2022."},{"issue":"2","key":"1312_CR40","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijerph20021526","volume":"20","author":"VR Carlisle","year":"2023","unstructured":"Carlisle VR, Maynard OM, Bagnall D, Hickman M, Shorrock J, Thomas K, et al. Should I stay or should I go?? A qualitative exploration of stigma and other factors influencing opioid agonist treatment journeys. Int J Environ Res Public Health. 2023;20(2):1526.","journal-title":"Int J Environ Res Public Health"},{"key":"1312_CR41","unstructured":"Johnstone L. Straight talking introduction to psychiatric diagnosis. Pccs Books; 2014."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01312-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01312-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:09:18Z","timestamp":1759165758000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-025-01312-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01312-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}